Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulcardine
- Development stage
- Phase 2
- Lead developer
- HUYABIO International, LLC.
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
HBI-3020 is an oral, second-generation antiarrhythmic drug in development for the maintenance therapy of chronic atrial fibrillation (AF). It is a multi-ion channel blocker that inhibits several cardiac ion channels (including INa-peak, INa-late, ICa,L, and IKr/hERG) with similar potency. The active pharmaceutical ingredient is sulcardine. This mechanism aims to provide rhythm control while minimizing the risk of proarrhythmia and QT prolongation—a significant limitation of many current antiarrhythmic drugs. HBI-3020 is being developed by HUYA Bioscience International as an oral formulation following the intravenous form (HBI-3000), with a focus on safer long-term management of AF[1][2][3][4].
- Other names
- sulcardine
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)KCNH2 (Voltage-gated potassium channel subfamily H member 2)
Beyond the preview
Go deeper on sulcardine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulcardine.